抗菌薬耐性診断薬の世界市場

抗菌薬耐性診断薬の世界市場は2030年までに61億米ドルに達する見込み

2024年に45億米ドルと推定される抗菌薬耐性診断薬の世界市場は、分析期間2024-2030年にCAGR 5.3%で成長し、2030年には61億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるPCR技術は、CAGR6.5%を記録し、分析期間終了時には17億米ドルに達すると予測されます。イムノアッセイ技術分野の成長率は、分析期間中CAGR 5.6％と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 8.5％で成長予測

米国の抗菌薬耐性診断薬市場は、2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.2％と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界の抗菌薬耐性診断薬市場- 主要動向と促進要因まとめ

抗菌薬耐性（AMR）診断薬が世界的に注目される理由とは？抗菌薬耐性（AMR）の憂慮すべき増加により、診断薬は薬剤耐性感染症の脅威と闘うための重要なツールと位置づけられています。細菌、ウイルス、真菌、寄生虫が標準治療に対する耐性を獲得する中、耐性株を迅速かつ正確に検出する能力は、効果的な患者管理にとって極めて重要です。院内感染（HAI）や多剤耐性（MDR）病原体の増加により、迅速かつ正確なAMR診断薬の導入が必要となっています。公衆衛生機関が早期発見の必要性を強調する中、政府や民間ヘルスケア機関はAMR診断技術に多額の投資を行っています。これらの進歩は、不適切な抗生物質の使用を減らし、患者に合わせた治療を行うことで、最終的に耐性菌の蔓延を緩和するために不可欠です。

技術革新はどのように診断精度を高めているのか？分子診断学、AIを駆使した分析ツール、次世代シーケンサー（NGS）における最近の進歩は、AMR検出のスピードと精度を大幅に向上させています。PCRベースのアッセイと全ゲノムシークエンシングにより、ヘルスケアプロバイダーは耐性遺伝子を驚くべき精度で特定できるようになっています。さらに、バイオセンサー、マイクロ流体デバイス、ポイントオブケア検査（POCT）キットは、現場での迅速な検査を可能にし、AMR診断に革命をもたらしています。これらの開発により、臨床医は培養ベースの検査結果を長期間待つことなく、データに基づいた治療方針を決定できるようになりました。また、機械学習アルゴリズムの診断プラットフォームへの統合により、病原体の同定と耐性プロファイリングが効率化され、診断の所要時間が短縮されています。

AMR診断市場に存在する課題と機会とは？AMR診断薬の重要な役割にもかかわらず、高コスト、規制上のハードル、低リソース環境でのアクセス制限などの課題が、普及の妨げとなっています。特に発展途上国の多くのヘルスケア施設では、高度な診断ソリューションを導入するために必要なインフラが整っていないです。しかし、市場機会は、資源が限られた地域向けに設計された、手頃な価格で使いやすい診断技術の拡大にあります。官民パートナーシップや資金提供イニシアティブが、費用対効果の高い診断プラットフォームの研究を推進し、より幅広いアクセシビリティを確保しています。さらに、WHOとCDCによるAMRサーベイランスと診断を促進する世界のイニシアチブが、より高い認識と政策主導型の市場成長を促進しています。

AMR診断市場の主な成長促進要因は？抗菌薬耐性診断薬市場の成長は、薬剤耐性感染症の負担の増加、迅速診断技術への投資の増加、AMR対策プログラムに対する規制当局の支援の拡大など、いくつかの要因によってもたらされます。個別化医療と精密診断の出現は、革新的なAMR検出ツールに対する需要を加速させています。さらに、政府主導の抗菌薬スチュワードシップ・プログラムの拡大が、臨床ワークフローへの迅速診断検査の統合を促しています。AIを活用した診断ソリューションの採用が増加していることに加え、バイオテクノロジー企業とヘルスケア機関のコラボレーションが市場拡大をさらに後押ししています。さらに、疾患の早期発見によるヘルスケアコスト削減の世界の推進は、AMR診断薬への投資を拡大し、この分野の持続的成長を位置づけています。

セグメント

技術（PCR技術、免疫測定技術、微生物培養技術、NGS技術、迅速・ポイントオブケア診断技術、その他の技術）、エンドユーザー（病院エンドユーザー、診断ラボエンドユーザー、製薬・バイオテクノロジー企業エンドユーザー、その他のエンドユーザー）

調査対象企業の例

• Abbott Laboratories, Inc.
• Accelerate Diagnostics, Inc.
• Acurx Pharmaceuticals, Inc.
• Becton, Dickinson and Company
• bioMerieux SA
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Hologic, Inc.
• Innoviva Inc
• Nabriva Therapeutics US, Inc.
• Paratek Pharmaceuticals, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Antimicrobial Resistance Diagnostics Market to Reach US$6.1 Billion by 2030

The global market for Antimicrobial Resistance Diagnostics estimated at US$4.5 Billion in the year 2024, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. PCR Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.5% CAGR

The Antimicrobial Resistance Diagnostics market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Antimicrobial Resistance Diagnostics Market - Key Trends & Drivers Summarized

Why Is Antimicrobial Resistance (AMR) Diagnostics Gaining Global Attention? The alarming rise of antimicrobial resistance (AMR) has positioned diagnostics as a critical tool in combating the threat of drug-resistant infections. As bacteria, viruses, fungi, and parasites develop resistance to standard treatments, the ability to quickly and accurately detect resistant strains is crucial for effective patient management. The increasing prevalence of hospital-acquired infections (HAIs) and multidrug-resistant (MDR) pathogens has necessitated the adoption of rapid and precise AMR diagnostics. With public health organizations stressing the need for early detection, governments and private healthcare entities are investing heavily in AMR diagnostic technologies. These advancements are vital in reducing inappropriate antibiotic use and tailoring patient-specific treatments, ultimately mitigating the spread of resistance.

How Are Technological Innovations Enhancing Diagnostic Accuracy? Recent advancements in molecular diagnostics, AI-powered analytical tools, and next-generation sequencing (NGS) are significantly improving the speed and precision of AMR detection. PCR-based assays and whole-genome sequencing are enabling healthcare providers to identify resistance genes with remarkable accuracy. Furthermore, biosensors, microfluidic devices, and point-of-care testing (POCT) kits are revolutionizing AMR diagnostics by facilitating rapid on-site testing. These developments allow clinicians to make data-driven treatment decisions without waiting for prolonged culture-based test results. The integration of machine learning algorithms into diagnostic platforms is also streamlining pathogen identification and resistance profiling, enhancing efficiency and reducing diagnostic turnaround time.

What Challenges and Opportunities Exist in the AMR Diagnostics Market? Despite the critical role of AMR diagnostics, challenges such as high costs, regulatory hurdles, and limited accessibility in low-resource settings hinder widespread adoption. Many healthcare facilities, especially in developing nations, lack the necessary infrastructure to implement advanced diagnostic solutions. However, market opportunities lie in the expansion of affordable, easy-to-use diagnostic technologies designed for resource-limited regions. Public-private partnerships and funding initiatives are driving research into cost-effective diagnostic platforms, ensuring wider accessibility. Additionally, global initiatives by WHO and CDC promoting AMR surveillance and diagnostics are fostering greater awareness and policy-driven market growth.

What Are the Key Growth Drivers of the AMR Diagnostics Market? The growth in the antimicrobial resistance diagnostics market is driven by several factors, including the rising burden of drug-resistant infections, increased investment in rapid diagnostic technologies, and growing regulatory support for AMR control programs. The emergence of personalized medicine and precision diagnostics is accelerating demand for innovative AMR detection tools. Additionally, the expansion of government-led antimicrobial stewardship programs is encouraging the integration of rapid diagnostic testing into clinical workflows. The rising adoption of AI-driven diagnostic solutions, along with collaborations between biotech firms and healthcare institutions, is further propelling market expansion. Moreover, the global push for reducing healthcare costs through early disease detection is amplifying investments in AMR diagnostics, positioning this sector for sustained growth.

SCOPE OF STUDY:

The report analyzes the Antimicrobial Resistance Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid and Point-of-Care Diagnostics Technology, Other Technologies); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Pharma and Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories, Inc.
• Accelerate Diagnostics, Inc.
• Acurx Pharmaceuticals, Inc.
• Becton, Dickinson and Company
• bioMerieux SA
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Hologic, Inc.
• Innoviva Inc
• Nabriva Therapeutics US, Inc.
• Paratek Pharmaceuticals, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Antimicrobial Resistance Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Need for Rapid Diagnostic Solutions Amid Increasing AMR Cases
  • Growing Investments in AI-Powered Pathogen Detection Technologies
  • Advancements in Molecular Diagnostics Enhancing AMR Detection Accuracy
  • Increasing Adoption of Point-of-Care AMR Testing Solutions
  • Surging Demand for Genomic & Next-Generation Sequencing in AMR Diagnostics
  • Expansion of Portable & Handheld AMR Diagnostic Devices for Remote Testing
  • Growing Integration of Smart Sensors & Digital Health Platforms in AMR Testing
  • Increasing Focus on Personalized Treatment Strategies Using AMR Diagnostics
  • Government & Public Health Initiatives Supporting Early AMR Detection
  • Collaboration Between Diagnostic Companies & Pharmaceutical Firms to Combat AMR
  • Rising Awareness & Adoption of AMR Diagnostic Kits in Veterinary Medicine
  • Evolving Laboratory Automation Trends Driving Efficiency in AMR Detection
  • Emergence of Cost-Effective AMR Diagnostic Solutions for Low-Resource Settings
  • Growing Reimbursement Support & Insurance Coverage for AMR Testing
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antimicrobial Resistance Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for PCR Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for PCR Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for PCR Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Microbiology Culture Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Microbiology Culture Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Microbiology Culture Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for NGS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for NGS Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for NGS Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Rapid & Point-of-Care Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Rapid & Point-of-Care Diagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Rapid & Point-of-Care Diagnostics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: France 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: France 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Germany 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Germany 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Italy 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Italy 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: UK 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: UK 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Spain 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 95: Spain Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Spain Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Spain 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Russia 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 101: Russia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Russia Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Russia 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Rest of Europe 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Australia 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 122: Australia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Australia Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Australia 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 125: India Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: India 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 128: India Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: India Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: India 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: South Korea 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 134: South Korea Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: South Korea Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: South Korea 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Asia-Pacific Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Argentina 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 155: Argentina Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Argentina Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Argentina 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Brazil 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 161: Brazil Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Brazil Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Brazil 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Mexico 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 167: Mexico Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Mexico Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Mexico 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Latin America Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Latin America 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Antimicrobial Resistance Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Iran 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 188: Iran Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Iran Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Iran 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Israel 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 194: Israel Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Israel Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Israel 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Saudi Arabia Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Saudi Arabia 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: UAE 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 206: UAE Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UAE Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: UAE 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Middle East Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Middle East 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Antimicrobial Resistance Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Antimicrobial Resistance Diagnostics by Technology - PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Africa 15-Year Perspective for Antimicrobial Resistance Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR Technology, Immunoassay Technology, Microbiology Culture Technology, NGS Technology, Rapid & Point-of-Care Diagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • TABLE 218: Africa Recent Past, Current & Future Analysis for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Africa Historic Review for Antimicrobial Resistance Diagnostics by End-Use - Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Africa 15-Year Perspective for Antimicrobial Resistance Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals End-Use, Diagnostic Laboratories End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION